MYCN and astrocytoma (excluding glioblastoma): Therefore, research on potential interactions between PIK3R1/Notch1/Mycn alteration and CDKN2A/B homozygous deletion may shed light on the mechanism and therapeutic target on molecular astrocytoma, IDH‐mutant, Grade 4.